JNJ Anssen Submits Supplemental Biologics License Application To U.S. FDA Seeking Approval Of CARVYKTI For Earlier Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
JNJ's Anssen has submitted a supplemental Biologics License Application to the U.S. FDA, seeking approval for CARVYKTI to treat patients with relapsed or refractory multiple myeloma at an earlier stage.
June 06, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JNJ's Anssen seeks FDA approval for CARVYKTI to treat relapsed or refractory multiple myeloma patients earlier, potentially expanding the drug's market.
JNJ's Anssen is seeking FDA approval for CARVYKTI to treat patients with relapsed or refractory multiple myeloma at an earlier stage. If approved, this could expand the drug's market and potentially increase JNJ's revenues. The news is directly related to JNJ and has a high importance for investors, as it could impact the company's financial performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100